<DOC>
	<DOCNO>NCT00156962</DOCNO>
	<brief_summary>The purpose study look subject incidence adverse event .</brief_summary>
	<brief_title>Epoetin Alfa ( EPO ) Subjects With Chronic Kidney Disease ( CKD )</brief_title>
	<detailed_description>To determine whether Epoetin alfa manufacture roller bottle technology ( Epoetin alfa RB ) Epoetin alfa manufacture deep tank process ( Epoetin alfa DT ) comparable safety profile administer patient CKD dialysis .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>â‰¥ 18 year age CKD dialysis : estimate glomerular filtration rate ( GFR ) 15mL/min 60 mL/min ( Modification Diet Renal Disease [ MDRD ] equation ) Clinically stable Mean screening/baseline hemoglobin ( Hb ) value 11.0 13.0 g/dL Currently receive Epoetin alfa RB ( ie . Epogen Procrit ) dose frequency least four week prior randomization 1 missed withheld dose 2 week period Adequate iron store ( transferrin saturation &gt; 15.0 % ) No prior use erythropoietic agent Epogen , Procrit Aranesp Currently receive treatment erythropoietic stimulating protein Epogen Procrit . Prior use erythropoietic agent Epogen , Procrit Aranesp . Uncontrolled hypertension ( define diastolic blood pressure [ BP ] &gt; 110 mmHg systolic BP &gt; 180 mmHg screening ) . Grand mal seizure within last 6 month prior screen . Acute myocardial ischemia ; hospitalization congestive heart failure myocardial infarction within 12 week randomization . Stroke ( hemorrhagic ischemic ) transient ischemic attack within 12 week randomization . Major surgery within 3 month prior screen ( exclude vascular access surgery ) . Clinical evidence systemic infection inflammatory disease time screen randomization . Known history severe hyperparathyroidism ( intact parathyroid hormone [ iPTH ] &gt; 1500 pg/ml biointact parathyroid hormone [ biPTH ] &gt; 800 pg/ml within 3 month prior randomization ) . Known positivity HIV antibody hepatitis B surface antigen . Clinical evidence current malignancy exception basal cell squamous cell carcinoma skin . Blood transfusion within 8 week prior screen active bleeding . Androgen therapy within 8 week prior screen . Interferon therapy . Patients know tested positive time past antibody erythropoietic protein . Systemic hematological disease ( eg . sickle cell anemia , myelodysplastic syndrome , hematological malignancy ) ; myeloma ; hemolytic anemia . Other investigational product exclude . Subject currently enrol , yet complete period least 30 day since end investigational device drug trial ( ) . Psychiatric , addictive , disorder compromise ability give truly informed consent participation study . Pregnant breast feeding ( woman childbearing potential must take adequate contraceptive precaution ) . Anticipating schedule livingrelated kidney transplant . Currently receive home hemodialysis treatment . Currently receive immunosuppressive therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Epogen</keyword>
	<keyword>Procrit</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Anemia Treatment</keyword>
</DOC>